Serotonin-2 Receptor Agonists as Novel Ocular Hypotensive Agents and their Cellular and Molecular Mechanisms of Action: Novel Drug Targets for Glaucoma Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|11|8|978-993

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.8, 2010-01, pp. : 978-993

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel natural vanilloid receptor agonists: new therapeutic targets for drug development

By Sterner O.   Szallasi A.  

Trends in Pharmacological Sciences, Vol. 20, Iss. 11, 1999-11 ,pp. : 459-465

Elsevier

Access to resources Recommend Favorite

Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2811-2829

Bentham Science Publishers

Access to resources Recommend Favorite

Novel antagonist implicates the CB 1 cannabinoid receptor in the hypotensive action of anandamide

By Varga K.   Lake K.   Martin B.R.   Kunos G.  

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 279-283

Elsevier

Access to resources Recommend Favorite

Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain

By  

Current Medicinal Chemistry, Vol. 20, Iss. 11, 2013-04 ,pp. : 1409-1436

Bentham Science Publishers

Access to resources Recommend Favorite

Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma

By  

Current Drug Delivery, Vol. 13, Iss. 6, 2016-09 ,pp. : 818-829

Bentham Science Publishers

Access to resources Recommend Favorite